Gilead Sciences hasn't been performing well in the stock market for a while. The company's stock peaked in 2015 and then was in a downtrend till 2017. Since then, the stock has been trading sideways.
Looking deeper into the company, the company has a few growth drivers worth noting.
- Lenacapavir, a twice-a-year injectable treatment for HIV
- Trodelvy, a cancer drug
For Lenacapavir, that drug is currently undergoing clinical trials and could soon receive FDA approval. The reason why many are optimistic about that drug is that it provides a great alternative to daily pills.
As for Trodelvy, that drug was approved last year. According to
The Motley Fool, Trodelvy could generate $5 billion in annual revenue at its peak.
Thoughts?